Saturday, April 20, 2024

Roche to Showcase Robust MS and NMOSD Real-World Data at ECTRIMS-ACTRIMS 2023

Similar articles

Roche to unveil new clinical and real-world data at ECTRIMS-ACTRIMS 2023 demonstrating the robustness of long-term results in MS and NMOSD.

Roche is set to present a comprehensive range of data at the 9th Joint ECTRIMS-ACTRIMS Meeting, including late-breaking results from Phase III trials of the subcutaneous OCREVUS (ocrelizumab) injection and Phase II trials of the BTK inhibitor fenebrutinib in multiple sclerosis (MS).

The data demonstrates the sustained effectiveness and safety of OCREVUS in MS over 10 years and its positive impact on underrepresented populations, including pregnant women and Black and Hispanic/Latinx patients.

Additionally, Roche will share longer-term safety data and late-breaking efficacy data for ENSPRYNG (satralizumab) in neuromyelitis optica spectrum disorder (NMOSD). These innovations aim to enhance the quality of life for individuals living with MS and NMOSD.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article